Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Eikon Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Eikon Therapeutics, Inc.’s stock price such as:

• Eikon Therapeutics, Inc.’s current stock price and volume
• Why Eikon Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for EIKN from analysts
• EIKN’s stock price momentum as measured by its relative strength

About Eikon Therapeutics, Inc. (EIKN)

Before we jump into Eikon Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor. The company was incorporated in 2019 and is based in Millbrae, California.

Want to learn more about Eikon Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Eikon Therapeutics, Inc..

What Caused Eikon Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 30, 2026, there were analysts who downgraded Eikon Therapeutics, Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Eikon Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Eikon Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Eikon Therapeutics, Inc. (EIKN) by visiting AAII Stock Evaluator.

Relative Price Strength of Eikon Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 30, 2026, Eikon Therapeutics, Inc. has a weighted four-quarter relative price strength of %, which translates to a Momentum Score of and is considered to be NA.

Want to learn more about how Eikon Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Eikon Therapeutics, Inc. Stock Price: Bottom Line

As of May 1, 2026, Eikon Therapeutics, Inc.’s stock price is $9.650, which is up 0.36% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Eikon Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.